Research progress in molecular biology of pediatric myelodysplastic syndrome
REN Yuan-Yuan, ZHU Xiao-Fan
Department of Pediatric Hematology, Chinese Academy of Medical Science, Peking Union Medical College, Institute of Hematology Hospital of Blood Disease, Tianjin 300020, China
Abstract：Marked differences have been found in molecular characteristics between pediatric and adult myelodysplastic syndrome（MDS) patients. The incidence of gene mutations associated with myeloid malignances in pediatric patients is lower than in adults, while the incidence of aberrant methylation is similar between them. It is also worth noting that novel molecular factors such as mitochondrial DNA mutations may play a role in the pathogenesis of childhood MDS. This article summarizes research advances in molecular biology of pediatric MDS.
Hasle H, Baumann I, Bergstrsser E, et al.The International Prognostic Scoring System（IPSS) for childhood myelodysplastic syndrome（MDS) and juvenile myelomonocytic leukemia（JMML)[J].Leukemia, 2004, 18(12): 2008-2014.
[2]
Pui CH, Carroll WL, Meshinchi S, et al.Biology, risk stratification, and therapy of pediatric acute leukemias: an update[J].J Clin Oncol, 2011, 29(5): 551-565.
[3]
Niemeyer CM, Baumann I.Classification of childhood aplastic anemia and myelodysplastic syndrome[J].Hematol Am Soc Hematol Educ Program, 2011, 2011: 84-89.
[4]
Hasle H, Niemeyer CM.Advances in the prognostication and management of advanced MDS in children[J].Br J Haematol,2011, 154(2): 185-195.
[5]
Elghetany MT.Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series[J].Arch Pathol Lab Med, 2007, 131(7):1110-1116.
[6]
Hasle H, Niemeyer CM, Chessells JM, et al.A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases[J].Leukemia, 2003, 17(2): 277-282.
[7]
Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization（WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J].Blood, 2009, 114(5): 937-951.
Göhring G, Michalova K, Beverloo HB, et al.Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome[J].Blood, 2010,116(19): 3766-3769.
[10]
McDonald S, Wilson DB, Pumbo E, et al.Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association[J].Pediatr Blood Cancer, 2010, 54(1): 154-157.
[11]
Kelly LM, Gilliland DG.Genetics of myeloid leukemias[J].Annu Rev Genomics Hum Genet, 2002, 3: 179-198.
[12]
de Vries ACH, Zwaan CM, Jansen JH, et al.Molecular aberrations in 107 children with myelodysplastic syndrome（MDS)[M]// Molecular Determinants of Juvenile Myelomonocytic Leukemia and Childhood Myelodysplastic Syndrome.Rotterdam: Erasmus University Rottedam, 2012: 75.
[13]
Grisendi S, Bernardi R, Rossi M, et al.Role of nucleophosmin in embryonic development and tumorigenesis[J].Nature, 2005,437(7055): 147-153.
[14]
Biljana J, Vera B, Valerija D, et al.NPM1 gene mutations in children with myelodysplastic syndromes[J].Arch Biol Sci,2011, 63(3): 649-653.
[15]
Chan G, Cheung LS, Yang W, et al.Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells[J].Blood,2011, 117(16): 4253-4261.
[16]
Chen Y, Takita J, Hiwatari M, et al.Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies[J].Genes Chromosomes Cancer,2006, 45(6): 583-591.
[17]
Kales SC, Ryan PE, Nau MM, et al.Cbl and human myeloid neoplasms: the Cbl oncogene comes of age[J].Cancer Res,2010, 70(12): 4789-4794.
[18]
Shiba N, Kato M, Park MJ, et al.CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome[J].Leukemia, 2010, 24(5): 1090-1092.
[19]
Arlt A, Schäfer H.Role of the immediate early response 3（IER3) gene in cellular stress response, inflammation and tumorigenesis[J].Eur J Cell Biol, 2011, 90(6-7): 545-552.
[20]
de Vries ACH, Zwaan CM, Danen-van Oorschot A, et al.IER3 expression in childhood MDS[M]//Molecular Determinants of Juvenile Myelomonocytic Leukemia and Childhood Myelodysplastic Syndrome.Rotterdam: Erasmus University Rottedam, 2012: 91-102.
[21]
Graubert T, Walter MJ.Genetics of myelodysplastic syndromes:new insights[J].Hematol Am Soc Hematol Educ Program, 2011,2011: 543-549.
[22]
Rodrigues EF, Santos-Reboucas CB, Goncalves Pimentel MM,et al.Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome[J].Leuk Lymphoma, 2010, 51(10): 1887-1894.
[23]
Hasegawa D, Manabe A, Kubota T, et al.Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[J].Br J Haematol,2005, 128(6): 805-812.
[24]
Muramatsu H, Wang X, Xu Y, et al.Aberrant DNA methylation is associated with poor outcomes in juvenile myelomonocytic leukemia[J].Blood, 2013, 122(21): 517.
[25]
Vidal DO, Paixâo VA, Brait M, et al.Aberrant methylation in pediatric myelodysplastic syndrome[J].Leuk Res, 2007, 31(2):175-181.
[26]
Kim M, Kook H, Park HJ, et al.Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes[J].Acta Haematol, 2013, 130(2): 115-121.
[27]
Schildgen V, Wulfert M, Gattermann N.Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes[J].Exp Hematol, 2011, 39(6): 666-675.
[28]
Gupta M, Madkaikar M, Rao VB, et al.Mitochondrial DNA variations in myelodysplastic syndrome[J].Ann Hematol, 2013,92(7): 871-876.
[29]
de Vries ACH, Zwaan CM, Beverloo HB, et al.Mitochondrial DNA mutations are involved in the development of childhood myelodysplastic syndrome[M]//Molecular Determinants of Juvenile Myelomonocytic Leukemia and Childhood Myelodysplastic Syndrome.Rotterdam: Erasmus University Rottedam, 2012: 105-124.
[30]
Das S, Ferlito M, Kent OA, et al.Nuclear miRNA regulates the mitochondrial genome in the heart[J].Circ Res, 2012, 110(12):1596-1603.
[31]
Rhyasen GW, Starczynowski DT.Deregulation of microRNAs in myelodysplastic syndrome[J].Leukemia, 2012, 26(1): 13-22.
[32]
Khraiwesh B, Arif MA, Seumel GI, et al.Transcriptional control of gene expression by microRNAs[J].Cell, 2010, 140(1): 111-122.
[33]
Visconte V, Makishima H, Maciejewski JP, et al.Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders[J].Leukemia, 2012, 26(12):2447-2454.
[34]
Chesnais V, Kosmider O, Damm F, et al.Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia[J].Oncotarget, 2012, 3(11): 1284-1293.
[35]
Hirabayashi S, Flotho C, Moetter J, et al.Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML[J].Blood, 2012, 119(11): e96-e99.
[36]
Niemeyer CM, Kratz CP.Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options[J].Br J Haematol, 2008,140(6): 610-624.
[37]
Strahm B, Nöllke P, Zecca M, et al.Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study[J].Leukemia,2011, 25(3): 455-462.
[38]
Kantarjian H, Issa JP, Rosenfeld CS, et al.Decitabine improves patient outcomes in myelodysplastic syndromes[J].Cancer,2006, 106(8): 1794-1803.
[39]
Zhou J, Fu C, Sun A, et al.Decitabine as induction therapy for median to high risk myelodysplastic syndromes（MDS) and acute myeloid leukemia（AML) before allogeneic stem cell transplantation[J].Blood, 2013, 122(21): 5044.
[40]
Estey EH.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia（MDS) and acute myeloid（AML)[J].Leukemia, 2013, 27(9): 1803-1812.
